MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$4,086K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Maturities of short-term investm...
Stock-based compensation expense
Depreciation and amortization ex...
Non-cash lease expense
Negative Cash Flow Breakdown
Net loss
Accounts payable and accrued exp...
Prepaid expenses and other asset...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-6,457
-6,804
-7,275
-5,527
Depreciation and amortization expense
23
24
24
24
Stock-based compensation expense
335
370
353
339
Change in fair value of convertible notes
-
-
0
0
Non-cash lease expense
20
20
19
18
Accretion of net discounts on short-term investments
14
35
34
25
Interest accrued on convertible notes
-
-
0
0
Prepaid expenses and other assets
958
-382
-1,256
-153
Accounts payable and accrued expenses
-2,149
212
0
787
Operating lease liabilities
-28
-28
-28
-26
Net cash used in operating activities
-9,228
-5,859
-5,685
-4,257
Purchases of short-term investments
-
-
0
0
Maturities of short-term investments
5,142
4,976
5,000
5,349
Net cash provided by (used in) investing activities
5,142
4,976
5,000
5,349
Cash acquired in connection with the merger
-
-
0
0
Payments for merger transaction costs
-
-
0
429
Proceeds from exercise of stock options
-
-
1
107
Net cash provided by financing activities
-
-
1
-322
Net decrease in cash and cash equivalents
-4,086
-883
-684
770
Cash and cash equivalents - beginning of year
19,851
20,734
21,418
31,614
Cash and cash equivalents - end of period
15,765
19,851
20,734
21,418
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Maturities of short-term
investments
$5,142K
(-53.48%↓ Y/Y)
Net cash provided by
(used in) investing...
$5,142K
(125.17%↑ Y/Y)
Net decrease in cash
and cash...
-$4,086K
(62.74%↑ Y/Y)
Canceled cashflow
$5,142K
Stock-based compensation
expense
$335K
(-52.62%↓ Y/Y)
Depreciation and
amortization expense
$23K
(-51.06%↓ Y/Y)
Non-cash lease expense
$20K
(-42.86%↓ Y/Y)
Net cash used in
operating activities
-$9,228K
(31.93%↑ Y/Y)
Canceled cashflow
$378K
Net loss
-$6,457K
(-19.31%↓ Y/Y)
Accounts payable and
accrued expenses
-$2,149K
(-1728.03%↓ Y/Y)
Prepaid expenses and
other assets
$958K
(-44.21%↓ Y/Y)
Operating lease
liabilities
-$28K
(42.86%↑ Y/Y)
Accretion of net discounts
on short-term...
$14K
(-90.07%↓ Y/Y)
Buy us a coffee
Tvardi Therapeutics, Inc. (TVRD)
Tvardi Therapeutics, Inc. (TVRD)